Repeated Transarterial Radioembolization Adverse Event and Hepatotoxicity Profile in Cirrhotic Patients With Hepatocellular Carcinoma: A Single-Center Experience

Abstract

Purpose The study aimed to evaluate the adverse event (AE) and hepatotoxicity profile, including radioembolization induced liver disease (REILD), following repeat radioembolization (RE) to the same or overlapping vascular territories in patients with hepatocellular carcinoma (HCC) and limited functional hepatic reserve/cirrhosis. Methods Nine patients (seven male and two female; median age, 66 years) with cirrhosis and HCC who underwent repeat RE (cycle 1 and cycle 2) between January 2012 and August 2019 were included. Patient demographics, clinical and treatment history, and pertinent laboratory values were recorded at baseline and post-treatment time points over a period of four months. Post-RE AE/hepatotoxicity was assessed, organized by type and frequency, and graded by severity according to the National Cancer Institute common terminology criteria for adverse events, version 5.0 (CTCAE v5.0). To assess rudimentary comparisons for post-RE hepatotoxicity vs. factors of interest, Spearman's rank correlation/rho was calculated, and all relevant plots were constructed. Kaplan-Meier analysis was performed along with associated median survival time. All statistical analyses were performed with Stata v16.1. Results Following cycle 1, 22 objective AE were identified according to CTCAE v.5 (17 grade I, four grade II, and one grade III), with grade I, II, and III AE experienced by 78%, 33%, and 11% of patients, respectively. Following cycle 2, 19 objective AE were identified according to CTCAE v.5 (11 grade I, seven grade II, and one grade III), with grade I, II, and III AE experienced by 89%, 56%, and 11% of patients, respectively. A single patient developed REILD after cycle 1, which progressed to fatal REILD following cycle 2. Following cycle 2, an additional patient advanced from less severe hepatotoxicity to REILD. Following cycle 2, positive correlations between the higher model for end-stage liver disease (MELD; rho=0.70) and Child-Pugh (rho=0.74) scores and degree of post-RE hepatotoxicity/REILD appear to emerge. Post-repeat RE median overall survival was 12.5 months. Conclusion Post-RE hepatotoxicity following repeat RE to the same or overlapping vascular territories in patients with limited functional hepatic reserve/cirrhosis is a common occurrence with variable severity ranging from transient laboratory derangement to fatal REILD. Lack of a consensus REILD definition and grading scale results in non-uniform reporting of incidence as well as clinical and laboratory features of the disease process. Strides aimed at improving clinical characterization, forming a more complete diagnostic definition, and establishing a uniform grading system with respect to REILD are of particular importance and would ultimately improve repeat RE patient selection and risk management.

Radioembolisation mit Harz- und Glas-Mikrosphären

“…Frage muss eine erneute prätherapeutische Abklärung mit vollständiger Re-Evaluation des Patienten einschließlich Leberangiografie und MAA-Bildgebung durchgeführt werden. Wie bereits erwähnt, kann das Risiko einer REILD nach wiederholter TARE erhöht sein, sodass die genaue Dosimetrie und Aktivitätsberechnung von großer Bedeutung sind[125,126]. In verschiedenen Arbeitsgruppen konnte jedoch nachgewiesen werden, dass eine wiederholte TARE bei sorgfältiger Planung mit einem guten Ansprechen bei moderater Toxizität verbunden ist[127].Schlussfolgerung und AusblickDie TARE ist eine hochselektive Radionuklidtherapie von primären und sekundären Lebertumoren, die bei ausgewählten Patienten mit leberdominanter Erkrankung Anwendung findet.…”